HAE — HAEMONETICS CORP MASS
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About HAEMONETICS CORP MASS (HAE)
HAEMONETICS CORP MASS (HAE) appears in the most recent 13F filings of 4 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $105M. Across recent filings, tracked investors recorded 3 new positions, 0 increased, 0 reduced, and 1 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in HAE
How many top investors track HAE
A small number of top investors own this.
HAE Ownership Composition
How HAEMONETICS CORP MASS is held across tracked investor types, based on reported 13F positions.
- Other85.6%
- Hedge Funds14.4%
Tracked investors reporting HAE
- Ken GriffinMar 31, 2026Citadel AdvisorsShares280.9KValue$15.8M% Portfolio0.00%
- Steve CohenMar 31, 2026Point72 Asset ManagementShares56.9KValue$3.2M% Portfolio0.00%
- Izzy EnglanderMar 31, 2026Millennium ManagementShares9.8KValue$551.4K% Portfolio0.00%
- Ray DalioMar 31, 2026Bridgewater AssociatesShares48.4KValue$2.7M% Portfolio0.01%
Recent activity
- New$3.2MMay 15, 2026
- New$2.7MMay 15, 2026
- Sold$0(-100.00%)Feb 13, 2026
- New$2.9MNov 13, 2025
Frequently asked questions
- How many institutional investors hold HAE?
- 4 tracked institutional investors disclosed a position in HAE (HAEMONETICS CORP MASS) in their most recent 13F filing.
- Who is the largest institutional holder of HAE?
- Ken Griffin, Citadel Advisors, holds the largest disclosed position in HAE, valued at $105M.
- Did institutional ownership of HAE increase or decrease?
- Across recent 13F filings, tracked investors recorded 3 new positions, 0 increased, 0 reduced, and 1 fully exited HAE.
- Where does this HAE ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.